{'52WeekChange': 1.4162569,
 'SandP52WeekChange': 0.0644362,
 'address1': '975 Island Drive',
 'address2': 'Suite 201',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 83.74,
 'askSize': 800,
 'averageDailyVolume10Day': 273237,
 'averageVolume': 313596,
 'averageVolume10days': 273237,
 'beta': 0.983983,
 'beta3Year': None,
 'bid': 83.54,
 'bidSize': 3200,
 'bookValue': 9.803,
 'category': None,
 'circulatingSupply': None,
 'city': 'Redwood City',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 84.29,
 'dayLow': 82.425,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -36.451,
 'enterpriseToRevenue': None,
 'enterpriseValue': 3602073344,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 74.47657,
 'fiftyTwoWeekHigh': 139.99,
 'fiftyTwoWeekLow': 30.32,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 24594821,
 'forwardEps': -3.12,
 'forwardPE': -26.772436,
 'fromCurrency': None,
 'fullTimeEmployees': 96,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.10903,
 'heldPercentInstitutions': 1.0561,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/allakos.com',
 'longBusinessSummary': 'Allakos Inc. operates as a clinical stage '
                        'biopharmaceutical company. The company is developing '
                        'antolimab (AK002) for the treatment of eosinophilic '
                        'gastritis and eosinophilic gastroenteritis, chronic '
                        'urticaria, indolent systemic mastocytosis, and severe '
                        'allergic conjunctivitis. Allakos Inc. was founded in '
                        '2012 and is headquartered in Redwood City, '
                        'California.',
 'longName': 'Allakos Inc.',
 'market': 'us_market',
 'marketCap': 4073457408,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_225312313',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -93243000,
 'nextFiscalYearEnd': 1640908800,
 'open': 84.29,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 597 5002',
 'previousClose': 84.1,
 'priceHint': 2,
 'priceToBook': 8.520861,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 84.29,
 'regularMarketDayLow': 82.425,
 'regularMarketOpen': 84.29,
 'regularMarketPreviousClose': 84.1,
 'regularMarketPrice': 84.29,
 'regularMarketVolume': 277365,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 48766400,
 'sharesPercentSharesOut': 0.15020001,
 'sharesShort': 7324715,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6817497,
 'shortName': 'Allakos Inc.',
 'shortPercentOfFloat': 0.4028,
 'shortRatio': 21.91,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ALLK',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.996,
 'twoHundredDayAverage': 67.97223,
 'volume': 277365,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.allakos.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94065'}